The Discounted Cash Flow (DCF) valuation of Cytokinetics Inc (CYTK) is (114.96) USD. With the latest stock price at 40.43 USD, the upside of Cytokinetics Inc based on DCF is -384.3%.
Based on the latest price of 40.43 USD and our DCF valuation, Cytokinetics Inc (CYTK) is a sell. selling CYTK stocks now will result in a potential gain of 384.3%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 6.7% - 10.5% | 8.6% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (298.17) - (74.06) | (114.96) |
| Upside | -837.5% - -283.2% | -384.3% |